Literature DB >> 26644533

Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies?

Steven M Offer1, Robert B Diasio2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26644533     DOI： 10.1200/JCO.2015.64.2546

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  A Comprehensive Understanding of Dietary Effects on C. elegans Physiology.

Authors:  Jie-Jun Zhou; Lei Chun; Jian-Feng Liu
Journal:  Curr Med Sci       Date:  2019-10-14

2.  Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity.

Authors:  Vasileios Fragoulakis; Rossana Roncato; Chiara Dalle Fratte; Fabrizio Ecca; Marina Bartsakoulia; Federico Innocenti; Giuseppe Toffoli; Erika Cecchin; George P Patrinos; Christina Mitropoulou
Journal:  Am J Hum Genet       Date:  2019-05-30       Impact factor: 11.025

Review 3.  Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.

Authors:  Filippo Merloni; Nicoletta Ranallo; Laura Scortichini; Riccardo Giampieri; Rossana Berardi
Journal:  Cancer Drug Resist       Date:  2019-09-19

4.  Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C. elegans.

Authors:  Timothy A Scott; Leonor M Quintaneiro; Povilas Norvaisas; Prudence P Lui; Matthew P Wilson; Kit-Yi Leung; Lucia Herrera-Dominguez; Sonia Sudiwala; Alberto Pessia; Peter T Clayton; Kevin Bryson; Vidya Velagapudi; Philippa B Mills; Athanasios Typas; Nicholas D E Greene; Filipe Cabreiro
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

5.  A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening.

Authors:  Chi C Tong; Ching W Lam; Ka O Lam; Victor H F Lee; Mai-Yee Luk
Journal:  Front Oncol       Date:  2018-07-24       Impact factor: 6.244

6.  Composition of fecal microbiota in low-set rectal cancer patients treated with FOLFOX.

Authors:  Jing Li; Jingtao Li; Na Lyu; Yue Ma; Fei Liu; Yuqing Feng; Li Yao; Zhiyong Hou; Xiaofeng Song; Hongchuan Zhao; Xiaoya Li; Yingdian Wang; Cheng Xiao; Baoli Zhu
Journal:  Ther Adv Chronic Dis       Date:  2020-02-26       Impact factor: 5.091
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.